Nature de la demande
Radiation
Arrêt du remboursement suite à un arrêt de commercialisation.
Avis favorable à l’arrêt du remboursement de la spécialité IMBRUVICA (ibrutinib) 140 mg, gélule dans les indications de l’AMM.
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
McER5unGPt2eRk5N
